Tags

Type your tag names separated by a space and hit enter

A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report.
JAMA. 2012 Jun 20; 307(23):2491-2.JAMA

Authors+Show Affiliations

Cardiovascular Health Research Unit, Department of Medicine, University of Washington and Group Health Research Institute, Group Health Cooperative, Seattle, Washington 98101, USA. psaty@u.washington.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

22563032

Citation

Psaty, Bruce M., et al. "A Lifecycle Approach to the Evaluation of FDA Approval Methods and Regulatory Actions: Opportunities Provided By a New IOM Report." JAMA, vol. 307, no. 23, 2012, pp. 2491-2.
Psaty BM, Meslin EM, Breckenridge A. A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. JAMA. 2012;307(23):2491-2.
Psaty, B. M., Meslin, E. M., & Breckenridge, A. (2012). A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. JAMA, 307(23), 2491-2. https://doi.org/10.1001/jama.2012.5545
Psaty BM, Meslin EM, Breckenridge A. A Lifecycle Approach to the Evaluation of FDA Approval Methods and Regulatory Actions: Opportunities Provided By a New IOM Report. JAMA. 2012 Jun 20;307(23):2491-2. PubMed PMID: 22563032.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. AU - Psaty,Bruce M, AU - Meslin,Eric M, AU - Breckenridge,Alasdair, PY - 2012/5/8/entrez PY - 2012/5/9/pubmed PY - 2012/7/20/medline SP - 2491 EP - 2 JF - JAMA JO - JAMA VL - 307 IS - 23 SN - 1538-3598 UR - https://www.unboundmedicine.com/medline/citation/22563032/A_lifecycle_approach_to_the_evaluation_of_FDA_approval_methods_and_regulatory_actions:_opportunities_provided_by_a_new_IOM_report_ L2 - https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2012.5545 DB - PRIME DP - Unbound Medicine ER -